Table 5: Comparison between HPGP and LPGP groups at the 2-year follow-up (time III).
|
|
HPGP (n = 277) |
LPGP (n = 237) |
p-value |
||
|
Age (years), median (IQR) |
50.10 (36.93-62.10) |
55.74 (44.00-62.91) |
0.005* |
||
|
Men, n (%) |
210 |
75.81% |
174 |
73.42% |
0.99 |
|
Women, n (%) |
67 |
24.19% |
63 |
26.58% |
0.99 |
|
Vascular E., n (%) |
156 |
56.32% |
140 |
27.24% |
0.99 |
|
Traumatic E., n (%) |
108 |
21.01% |
80 |
15.56% |
0.79 |
|
Neoplastic E., n (%) |
7 |
1.36% |
9 |
1.75% |
0.985 |
|
Infectious E., n (%) |
2 |
0.39% |
5 |
0.97% |
0.931 |
|
Congenital E., n (%) |
4 |
0.78% |
3 |
0.58% |
1 |
HPGP: Higher Prosthetic Gait Performance group; LPGP: Lower Prosthetic Gait Performance; E: Aetiology; n: Number of persons; IQR: Interquartile range; p-value: Significance level according to the Fisher’s exact test; *p-value according to the Mood’s test